IMAB I-Mab

Nasdaq i-mabbiopharma.com


$ 6.11 $ -0.04 (-0.65 %)    

Thursday, 16-Oct-2025 12:01:26 EDT
QQQ $ 602.84 $ -2.37 (-0.39 %)
DIA $ 461.91 $ -1.39 (-0.3 %)
SPY $ 664.06 $ -2.87 (-0.43 %)
TLT $ 90.88 $ 0.38 (0.42 %)
GLD $ 393.25 $ 2.09 (0.53 %)
$ 6.13
$ 6.15
$ 6.10 x 200
$ 6.13 x 845
$ 5.97 - $ 6.50
$ 0.60 - $ 6.72
1,499,491
na
49.96M
$ 1.32
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 i-mab-to-present-updated-phase-1-givastomig-data-in-gastroesophageal-cancer-at-major-oncology-conference

I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncolog...

 leerink-partners-initiates-coverage-on-i-mab-with-outperform-rating-announces-price-target-of-9

Leerink Partners analyst Daina Graybosch initiates coverage on I-MAB (NASDAQ:IMAB) with a Outperform rating and announces Pr...

 btig-reiterates-buy-on-i-mab-maintains-7-price-target

BTIG analyst Justin Zelin reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $7 price target.

 btig-initiates-coverage-on-i-mab-with-buy-rating-announces-price-target-of-7

BTIG analyst Justin Zelin initiates coverage on I-MAB (NASDAQ:IMAB) with a Buy rating and announces Price Target of $7.

 needham-reiterates-buy-on-i-mab-maintains-6-price-target

Needham analyst Gil Blum reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $6 price target.

 i-mab-accelerates-givastomig-development-with-global-phase-2-trial-in-metastatic-gastric-cancer-expands-pipeline-and-appoints-wei-fu-as-executive-chairman

Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in ...

 hc-wainwright--co-reiterates-buy-on-i-mab-maintains-7-price-target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $7 price target.

 needham-maintains-buy-on-i-mab-raises-price-target-to-6

Needham analyst Gil Blum maintains I-MAB (NASDAQ:IMAB) with a Buy and raises the price target from $5 to $6.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION